Understanding Immunotherapy Response in Liver Cancer
Part of Cancer, Digestive system clinical trials.
This study collects tumor samples and medical information from patients with liver cancer to understand why some patients respond better to immunotherapy (immune-boosting drugs) than others. The goal is to improve treatment selection and outcomes for future patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18 or older
- Confirmed or suspected hepatocellular carcinoma (a type of liver cancer)
- Available tumor tissue from a biopsy or surgery
- Either previously treated with immunotherapy or targeted drugs, or scheduled to receive systemic treatment or local treatment (surgery/ablation)
- Able to provide informed consent for use of tissue samples and medical data
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a first-line immunotherapy combination (like atezolizumab + bevacizumab or similar drugs) for advanced liver cancer that can't be removed. It aims to see how well these treatments work and how safe they are in real-world patients.
This study looks at how well different combinations of interventional procedures (like TACE) and systemic treatments (like targeted therapy or immunotherapy) work for liver cancer. It uses real-world data to find which combinations might be best for different patients.
This study looks at how doctors can use imaging scans to predict how well immunotherapy will work for people with liver cancer that cannot be removed by surgery. Participants must have already received immunotherapy and have had baseline scans.
This study looks at how well a combination of liver-directed therapy and immunotherapy works for people with liver cancer that cannot be removed by surgery. It aims to find markers in your blood that might predict if the treatment will shrink the tumor enough to allow surgery later.
This study looks at how your immune cells respond to two specific immunotherapy-based treatments for advanced liver cancer. Researchers want to understand why some patients respond well and others do not, which could help improve future care.
This trial studies how liver cancer changes during immunotherapy and looks for biological markers that may predict treatment response. It helps doctors understand why some patients benefit more from treatment.
Hear when a new Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.